To understand the urgent need for resistance mechanisms to immune checkpoint blockade (ICB) therapy and to develop novel therapeutic strategies to enhance ICB efficacy.
Approach:
Overview of Resistance Mechanisms: Summarizes the tumor microenvironment (TME) components and the heterogeneous mechanisms contributing to resistance to ICB therapy.
Viral Mimicry Response: Introduces therapeutic approaches that trigger tumor-intrinsic innate immune responses through viral mimicry, including epigenetic therapies and DNA damage inducers.
Combination Strategies: Discusses opportunities for combining viral mimicry-based strategies with ICB therapy to overcome resistance.
Key Findings:
Resistance to ICB is often due to an immunologically 'cold' TME with few immune cell infiltrates.
Inducing tumor-intrinsic innate immune responses can convert 'cold' tumors to 'hot' tumors.
The TME's cellular and non-cellular components significantly influence ICB therapy responsiveness.
Interpretation:
The review highlights the importance of understanding TME-mediated resistance and suggests that activating innate immune responses may enhance the effectiveness of ICB therapy.
Limitations:
The review does not provide specific clinical trial data or outcomes related to the proposed strategies.
Further research is needed to validate the effectiveness of viral mimicry approaches in diverse tumor types.
Conclusion:
Inducing viral mimicry responses in tumors may represent a strategy to overcome resistance to ICB therapy.
